Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical products.
Please note: Not all treatments are available in all countries.

  • Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.

  • Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA

  • Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

  • Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination

  • Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

  • Novartis a enregistré, en 2015, une forte croissance des ventes et une hausse de sa marge core (tcc1) et annonce des plans pour accélérer la croissance d'Alcon et rationaliser les opérations du Groupe